These Apt-PEG-Au-NPs@5-FU nanocarriers have several advantages as a therapeutic option in cancer therapy, including 1) high drug loading capacity, 2) enhanced drug release rate at acidic pH, and 3) ability of targeting HT-29 tumors by EpCAM Apt-mediated mechanisms. The gene discussed is EPCAM; the disease is cancer.